Most Read Articles
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).

Infections predict death in diffuse large B cell lymphoma

16 Jul 2017
GIS, CSI make first collaborative discovery on cancer progression

Diffuse large B cell lymphoma (DLBCL) patients with neutropenia and multiple comorbidities have a high risk of death and infection, a new study reports. Moreover, infection is an independent predictor of survival.

In a cohort of 325 DLBCL patients, Charlson Comorbidity Index (CCI) scores of 3 to 5 (hazard ratio [HR], 2.16; 95 percent CI, 1.71 to 2.74; p<0.001) and ≥6 (HR, 3.91; 2.34 to 6.28; p<0.001) were significantly correlated with infections.

Having Eastern Cooperative Oncology Group (ECOG) scores of 1 (HR, 2.09; 1.46 to 3.01; p<0.001), 2 (HR, 3.33; 2.22 to 5.04; p<0.001) and 3 (HR, 3.36; 1.99 to 5.66; p<0.001), and neutropenia within 48 hours (HR, 2.46; 1.91 to 3.17; p<0.001) were also associated with increased risks of infection.

Over the study duration of 10 years, 99 deaths (30.5 percent) were reported. The median time from diagnosis to death was 273 (129 to 636) days. The most common cause of death was progressive lymphoma (58.6 percent), followed by infection (12.1 percent) and other cancers (5.5 percent).

CCI scores of 3 to 5 (HR, 4.34; 2.00 to 6.33; p<0.001) and ≥6 (HR, 7.36; 3.38 to 16.00; p<0.001), an ECOG status of 1 (HR, 2.61; 1.02 to 6.66; p=0.045) and 3 or 4 (HR, 7.16; 2.04to 25.06; p=0.002), and infection upon admission (HR, 3.27; 2.03 to 5.27; p<0.001) were all independent and significant predictors of survival.

Participants were recruited from Monash Health I Melbourne, Australia, and were receiving rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) or similar chemotherapies.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).